Cohance Lifesciences Ltd · NSE:COHANCE
Cohance Lifesciences — Suven Pharmaceuticals — H1 FY2023 Earnings Presentation
24 slides from Cohance Lifesciences's earnings presentation, November 2022
Slide 1: Suven Pharma Earnings Presentation Q2 & H1FY23
SUVEN PHARMA Earnings Presentation Q2 & H1FY23
Slide 2: Risk Statement
Risk Statement Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this presentation may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in
Slide 3: Table of Contents
4 14 Table of Operation & Financial Company Background Contents Performance Q2FY23 3
Slide 4: Operation & Financial Performance Q2FY23
Operation & Financial Performance Q2FY23 4
Slide 5: Businesswise data
Businesswise data CDMO Pharma CDMO Spec Chem Formulations & Other 151.54 Ser vices 144.36 137.34 19.3 108.43 18.43 Q2FY22 Q2FY23 Q2FY22 Q2FY23 Q2FY22 Q2FY23 Note: Figures in Rs. Crore 5
Slide 6: Businesswise data
Businesswise data CDMO Pharma CDM O Spec Chem Formulations & Other 318.66 297.74 Ser vices 268.89 44.84 222.21 29.65 H1FY22 H1FY23 H1FY22 H1FY23 H1FY22 H1FY23 Note: Figures in Rs. Crore 6
Slide 7: Financial Snapshot
Financial Snapshot Q2FY23 H1FY23 Growth in Growth in Growth in Revenue EBITDA PAT -17.42% -29.34% -30.80% 4.86% 0.77% -1.86% 7
Slide 8: Key Ratios
Key Ratios Q2FY23 H1FY23 Growth in EBITDA to PAT to EBIT Income Income -31.47% 40.52% 27.33% -0.37% 44.27% 30.22% 8
Slide 9: Financials Q2FY23
Financials Q2FY23 Revenue EBIDTA PAT EPS 1,656 4.5 4.5 3,497 1,601 1,152 3,393 1,141 2,888 1,170 789 3.1 RUPEES MN RUPEES MN RUPEES MN RUPEES Q2FY22 Q1FY23 Q2FY23 Q2FY22 Q1FY23 Q2FY23 Q2FY22 Q1FY23 Q2FY23 Q2FY21 Q1FY22 Q2FY22 9
Slide 10: Financials H1FY23
Financials H1FY23 Revenue EBIDTA PAT EPS 2,805 2,827 1,966 1,930 6,385 7.7 RUPEES MN RUPEES MN RUPEES MN RUPEES 7.6 6,089 H1FY22 H1FY23 H1FY22 H1FY23 H1FY22 H1FY23 H1FY22 H1FY23 10
Slide 11: Financials Q2FY23 margins
Financials Q2FY23 EBITDA Margin (%) PAT Margin (%) 47% 47% 41% 34% 33% 27% Q2FY22 Q1FY23 Q2FY23 Q2FY22 Q1FY23 Q2FY23 11
Slide 12: Financials H1FY23 margins
Financials H1FY23 EBITDA Margin (%) PAT Margin (%) 46% 44% 32% 30% H1FY22 H1FY23 H1FY22 H1FY23 12
Slide 13: Financial Snapshot – Q2 FY23
Financial Snapshot – Q2 FY23 Quarter ended Period ended 30-Sep-22 30-Jun-22 30-Sep-21 30-Sep-22 30-Sep-21 Revenue 2,887.91 3,496.97 3,393.23 6,384.88 6,089.08 EBITDA 1,170.32 1,656.37 1,601.10 2,826.69 2,805.10 EBITDA Margin 40.52% 47.37% 47.19% 44.27% 46.07% EBIT 1,062.76 1,550.89 1,509.33 2,613.66
Slide 14: Company Background
Company Background SUVEN 14 PHARMA
Slide 15: Business Model
Business Model Process Custom Research Synthesis Contract Development And Manufacturing Operations (CDMO) Formulation Clinical Development Supplies Mfg Analytical & & Packaging Services 15
Slide 16: Brief Profile
Brief Profile BUSINESS OVERVIEW KEY STRENGTHS o Integrated CDMO company with strong o Preferred global outsourcing FINANCIAL OVERVIEW capabilities right from partner with capabilities o Standalone Revenues, EBIT and PAT process research & across the entire CDMO of Rs 6385 Mn, Rs 2614 Mn and Rs devel
Slide 17: Overview
Overview Suven is an integrated Contract Development and Manufacturing Operations company Suven provides services to leading Global Life Science and Fine Chemical majors including Custom Synthesis, Process R&D, Scale Up and Contract Manufacturing of intermediates, APIs and formulations. Since our fo
Slide 18: Our Focus: NCE based CDMO
Our Focus NCE based A full-fledged bio- pharmaceutical solutions CDMO provider for global pharmaceutical companies 18 18
Slide 19: Financial Approach
Financial Approach Consistently Low dividend debt paying Shareholder Prudent value creation utilisation of focus cash flows 19
Slide 20: Business Drivers
Business Drivers Industry Relationship An integrated research service provider with Leveraging on unmatched capabilities research capabilities Present across the to delivering NCE entire CDMO value research chain – State of the art intermediates & facilities located APIs across India and US 20
Slide 21: Business Drivers
Business Drivers Execution Capabilities Over 90% of Working with revenues from innovator companies regulated in developed markets markets having stringent regulations – Long term reflection of our commercial supply research skills Repeat business with the launch of owing to long product by global st
Slide 22: Multi Location Facilities
Multi Location Facilities o o 300 CM reactors (93) 500L to 10 KL GL/SS o GMP Intermediates Vizag, Andhra Pashamylaram, Telangana, India Banjara Hills, Hyderabad, India Suryapet, Telangana, India Pradesh, India API & Formulation Facility Corporate Office Intermediate Mfg. Facility o 307 KL reactor vo
Slide 23: Contact
Contact For queries and requests, please contact: Sunder Venkatraman Suven Pharmaceuticals Ltd Suven Pharmaceuticals Ltd Tel: +91 939 248 3011 # 8-2-334, SDE Serene Chambers, Email: info@suvenpharm.com For more info: www.suvenpharm.com 3rd Floor, Road No. 5, Avenue - 7, Banjara Hills, Hyderabad-500
Slide 24: Thank You
Thank You 6 SUVEN PHARMA
Suven Pharmaceuticals — H1 FY2023 Earnings Presentation on 6ix